PT-141 (Bremelanotide)

Summary

PT-141 — generic name bremelanotide — is unusual among the peptides on this site: it is FDA-approved. Sold as Vyleesi, it is approved for one specific use — acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — and is given as an on-demand subcutaneous injection before anticipated sexual activity. What makes it mechanistically interesting is that it works on the brain's melanocortin system, not on blood flow the way Viagra-style drugs do, so it is often described as acting on desire rather than on the physical plumbing of an erection. The honest state of the evidence is two-sided: for its approved use, two Phase 3 trials show a real but modest effect; for the uses it is most aggressively marketed for online — men's erectile dysfunction and a general "libido shot" for anyone — the supporting evidence is older, early-stage, and in the case of men was discontinued in development rather than carried to approval.

What people use it for

The approved use is treating low sexual desire (HSDD) that causes distress in premenopausal women. Off-label and in the gray market, PT-141 is sold and discussed far more broadly: as an on-demand erectile-dysfunction and libido treatment for men, as a "desire" enhancer for people of any sex, and sometimes stacked with other peptides in biohacker circles. Much of this off-label use involves not the approved Vyleesi product but compounded or "research only" PT-141 of unverified content. The evidence sections below separate what the trials actually tested — and in whom — from what the broader marketing assumes.

Human evidence

PT-141 has genuine human trial data, but the strength of that data is very different across the uses people seek it for.

HSDD in premenopausal women (the approved use). The pivotal evidence is the RECONNECT program: two identical Phase 3, randomized, double-blind, placebo-controlled trials (Kingsberg et al., Obstetrics & Gynecology, 2019) of bremelanotide 1.75 mg taken subcutaneously as needed in premenopausal women with acquired, generalized HSDD. Both trials met their co-primary endpoints: women taking bremelanotide had statistically significant increases in sexual desire and statistically significant reductions in distress related to low desire versus placebo. This is the evidence that earned FDA approval, and it is legitimate, high-quality data. The important honest caveat is effect size: the improvements, while statistically significant, were modest, and the trials did not show a significant increase in the number of satisfying sexual events — so this is a real treatment with a measured, limited benefit, not a dramatic one. An open-label extension (Simon et al., Obstetrics & Gynecology, 2019) followed women longer and reported that the effect and tolerability were maintained, with no new safety signals. Because the studied population was specifically premenopausal women with a specific diagnosis, the data does not automatically extend to postmenopausal women or to people without HSDD.

Erectile dysfunction in men (older, discontinued). PT-141 was originally developed for men. Early-phase studies, including a Phase 2 double-blind, placebo-controlled trial of intranasal PT-141 (Diana / Rosen et al.), found a statistically significant erectogenic response at intranasal doses above ~7 mg, with erections beginning roughly 30 minutes after dosing. But development for men was not carried forward: the intranasal program was halted after dose-related blood-pressure increases, and the drug was ultimately developed and approved only as a subcutaneous treatment for women's HSDD. There is no modern Phase 3 evidence for PT-141 in men, and it is not approved for them — so today's widespread men's use rests on decade-plus-old early-stage data plus anecdote.

Animal / preclinical evidence

The mechanism is well characterized and is the reason PT-141 behaves differently from blood-flow drugs. Bremelanotide is a synthetic cyclic peptide analog of α-melanocyte-stimulating hormone (α-MSH) that acts as a melanocortin receptor agonist, non-selectively activating several melanocortin receptor subtypes, with activity at MC1R and MC4R considered most relevant at therapeutic doses. Activation of MC4R in the central nervous system is thought to be the route by which it influences sexual desire — a central, brain-level mechanism rather than a peripheral vascular one. The same melanocortin activity at MC1R (the receptor involved in skin pigmentation) explains one of its characteristic side effects, skin darkening. Notably, the FDA label itself states that the precise mechanism by which bremelanotide improves HSDD is unknown — the receptor pharmacology is understood, but the full path from receptor to desire is not. For a drug this far into human testing, the preclinical detail is mainly of mechanistic interest; the human trials above are what govern its use.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Online, PT-141 has a large anecdotal following well beyond its approved use — men and women report rapid, on-demand increases in arousal and libido a short time after injecting, often describing it as affecting "wanting" rather than mechanics. Reports also frequently mention the same effects seen in the trials: nausea (often strong, especially the first time) and flushing. Because the approved drug genuinely affects desire in the studied population, some carryover to other users is plausible — but effect, dosing, and safety in men, in postmenopausal women, and via non-approved routes have not been characterized at modern standards, and most community product is compounded or gray-market rather than the approved Vyleesi, adding the usual quality and contamination uncertainty.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

PT-141 (as Vyleesi) is a prescription medication whose use is determined and supervised by a licensed clinician; the figures here are study/label context only. The approved regimen is 1.75 mg by subcutaneous injection, used on demand at least 45 minutes before anticipated sexual activity, with the label specifying no more than one dose in 24 hours and no more than 8 doses per month. The historical men's-ED research used a different route entirely — intranasal PT-141 above ~7 mg (studied up to 20 mg) — a formulation that was discontinued and never approved. These figures describe what was administered to specific populations under study or label conditions. They are not a protocol to self-administer, and they do not transfer to compounded or "research only" product of unknown concentration.

Safety & side effects

Because PT-141 is approved as Vyleesi, its safety profile is characterized on an FDA label — a real advantage over gray-market peptides — but it carries meaningful warnings, and the side effects are common rather than rare.

Tolerability side effects are frequent. In the trials and on the label, the most common adverse reactions were nausea (reported by roughly 40% of users, often with the first injection and sometimes severe enough to need anti-nausea medication or to cause people to stop), flushing (~20%), injection-site reactions (~13%), and headache (~11%).

Blood pressure is the key cardiovascular caution. Bremelanotide causes a transient increase in blood pressure and a small decrease in heart rate after each dose — the label cites maximal increases on the order of about 6 mmHg systolic and 3 mmHg diastolic, with heart rate down up to ~5 beats per minute, usually resolving within about 12 hours. Because of this, it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease, and this blood-pressure effect is precisely why the earlier intranasal men's program was discontinued.

Skin darkening (focal hyperpigmentation). Through its melanocortin (MC1R) activity, bremelanotide can cause focal hyperpigmentation — darkening of areas such as the face, gums, and breasts. This was uncommon with the approved intermittent dosing (about 1% over up to 8 monthly doses) but far more common with frequent daily dosing (about 38% with daily use for 8 days), and people with darker skin were more likely to develop it; the label advises considering stopping the drug if it appears. More frequent dosing than the label allows raises this risk — directly relevant to gray-market use.

Other label points. The label advises discontinuing after 8 weeks if there is no improvement, and warns of a drug interaction: bremelanotide can significantly decrease the absorption of orally taken naltrexone, so it should not be used with oral naltrexone products taken for alcohol or opioid use disorder. Finally, gray-market/"research" PT-141 carries the usual unregulated-product risks (contamination, mislabeling, inaccurate dosing) on top of all of the above.

Regulatory / legal status

PT-141 (bremelanotide) is FDA-approved — the key difference from most peptides on this site. It was approved on June 21, 2019 as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and that remains its only approved indication. Used as prescribed for that purpose, it is a legal, regulated medicine.

Two boundaries define everything else. First, every other use is off-label or unapproved: the FDA approval does not cover men, erectile dysfunction, postmenopausal women, or use as a general libido enhancer, and those uses were not evaluated or authorized in the approval. Second, much of the PT-141 sold and used off-label is not the approved Vyleesi product but compounded or "research only" peptide — unapproved, unregulated, and of unverified content, a different risk category from the pharmacy drug. Regulatory and legal status varies by country and can change; this is not legal or medical advice.

Podcast / media mentions

PT-141 shows up constantly in men's-health, biohacking, and "sexual optimization" content as a fast-acting "libido peptide" or "the female Viagra" — framings that are both somewhat misleading. The accurate version: bremelanotide is FDA-approved, but narrowly — for low sexual desire in premenopausal women, where it works modestly, and it acts on the brain's desire pathways rather than on erections, so the "Viagra" comparison is mechanistically wrong. The biggest stretch in popular coverage is the confident promotion of PT-141 as an on-demand ED and libido shot for men: that use traces back to early-stage trials that were discontinued (largely over blood-pressure effects), not to modern approval-grade evidence, and it is typically done with gray-market product at self-chosen doses — exactly the pattern that raises the hyperpigmentation and blood-pressure risks the label flags. Where coverage keeps PT-141 in its evidentiary lane — an approved, modest treatment for a specific condition in women — it squares with the data; where it implies a proven, safe, universal libido drug, it runs well ahead of the evidence. As elsewhere, the critique is of the framing, not of a legitimately approved medicine.